查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1756476

基准标记市场，按产品、按方式、按癌症类型、按最终用户、按国家和地区 - 行业分析、市场规模、市场份额及预测（2024 年至 2032 年）

Fiducial Marker Market, By Product, By Modality, By Cancer Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 399 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年基准标记市场规模价值为 1.689 亿美元，2024 年至 2032 年的复合年增长率为 8.70%。

基准标记市场-市场动态

影像引导疗法的采用率不断提高

肿瘤科、神经科和心臟科越来越多地采用影像引导疗法，这是基准标记市场发展的关键驱动力。这些手术高度依赖解剖目标的高精度定位，以提高治疗准确性并减少併发症。基准标记作为可靠的参考点，在将影像资料与患者解剖结构对齐方面发挥着至关重要的作用，尤其是在立体定位放射外科或质子治疗等复杂干预措施中。随着医疗保健提供者越来越倾向于微创和标靶治疗方案，对基准标记的需求激增。此外，包括MRI、CT和混合PET/CT系统在内的影像技术的进步，扩展了基准标记在各种临床环境中的实用性。癌症和慢性病盛行率的上升进一步加剧了对精准治疗计画的需求，使得基准标记成为现代治疗工作流程中的重要工具。预计这一趋势将推动市场持续成长。

基准标记市场-关键见解

根据我们的研究分析师，全球基准标记市场预计在 2024 年至 2032 年期间的复合年增长率约为 8.70%。

按 2024 年的产品细分，金属基标记物类别占据了市场主导地位。

根据模式，超音波在 2024 年产生的收入最多。

按地区划分，2024年北美是收入最高的地区。

基准标记市场-細項分析：

全球基准标记市场分为四大类：产品、模式、癌症类型、最终用户和地区。

基准标记市场按产品细分为金属基标记、聚合物基标记和其他基准标记。其中，金属基标记因其卓越的可视性以及与CT、MRI和X射线等各种成像方式的兼容性，预计将占据市场主导地位。这些标记通常由金、铂或不銹钢製成，具有高对比度和体内长期稳定性，使其成为需要重复成像的程序的理想选择，例如放射治疗计划和影像引导手术。其耐用性和低迁移风险提高了程序的准确性，尤其是在肿瘤学应用中。金属基基准点在临床上的广泛认可，以及其在改善治疗效果方面的已证实的功效，进一步巩固了其市场领导地位。随着精准医疗和微创治疗需求的持续增长，金属基标记的强大性能和可靠性使其成为全球医疗保健系统的首选。

按癌症类型细分，基准标记市场包括摄护腺癌、肺癌、胃癌、乳癌和其他癌症。其中，前列腺癌占最大份额，预计仍将占据主导地位。这主要是因为基准标记在前列腺癌治疗的影像导引放射治疗 (IGRT) 和立体定位放射治疗 (SBRT) 中广泛使用。由于膀胱和直肠充盈，前列腺往往会轻微移位，因此准确定位至关重要。金属基准标记，尤其是金标记，通常被植入前列腺，以确保每次治疗期间的精确定位，从而改善治疗效果并最大限度地减少对周围组织的损伤。全球前列腺癌发生率的上升，以及人们对先进放射治疗技术的认识和采用的不断提高，正在推动该领域对基准标记的持续需求。临床方案的加强和报销支持进一步巩固了其市场主导地位。

基准标记市场-地理洞察

从地理分布来看，基准标记市场分布于北美、亚太地区、拉丁美洲、欧洲、中东和非洲。这些区域根据业务开展的国家进一步划分。

北美在基准标记市场占据主导地位，主要得益于其先进的医疗基础设施、影像引导疗法的高采用率以及对癌症治疗技术的大量投资。美国尤其引领市场，因为其癌症（尤其是前列腺癌和肺癌）发生率高，这推动了对基准标记等精准诊断和治疗工具的需求。此外，强大的报销政策加上完善的医疗保健体系，促进了基准标记在放射治疗和外科手术中的广泛应用。此外，微创治疗和影像技术的持续研究与创新也持续支撑着市场的成长。该地区的主导地位也得益于主要市场参与者的存在，这进一步推动了基准标记的应用和产品开发。

欧洲是另一个对基准标记市场贡献巨大的关键地区。先进医疗技术的采用，加上对精准医疗和标靶癌症治疗的日益重视，促进了该地区对基准标记的需求。德国、英国、法国和义大利等国家凭藉其高度发展的医疗体系和不断上升的癌症发生率，引领市场。欧洲医疗保健机构越来越多地在影像导引放射治疗中使用基准标记，尤其是在摄护腺癌、乳癌和肺癌治疗中。该地区强大的监管框架以及对临床研究和创新的支持，为基准标记使用量的成长铺平了道路。此外，对微创治疗的日益偏好以及对改善患者预后的日益关注，进一步推动了市场的发展。

基准标示市场-竞争格局：

基准标记市场的竞争态势由许多老牌企业和专注于创新的新兴公司共同塑造。 CIVCO Radiotherapy、波士顿科学公司、IZI Medical Products、美敦力和 IBA 等主要市场参与者占据了相当大的市场份额，提供针对各种医学成像应用量身定制的各种高品质基准标记。这些公司在研发方面投入巨资，以增强产品功能、提高精准度并确保合规性。 Nanovi A/S 和 Innovative Oncology Solutions 等新进业者正在推出先进技术，例如可视性更高、更易于植入的下一代基准标记。这种竞争格局推动了该领域的持续进步，创造了创新环境，最终提高了手术的准确性和有效性。例如，美敦力透过持续的研发和先进成像技术的开发，不断在该领域进行创新，并保持了其在市场上的领先地位。

最新动态：

2023年10月，丹麦医疗器材公司Nanovi A/S（专注于液体基准标记）被CQ Medical（前身为CIVCO Radiotherapy和Qfix）收购。此次收购将Nanovi的创新BioXmark(R)技术整合到CQ Medical的产品组合中，增强其在高精度放射治疗领域的产品组合。 BioXmark(R)是一种可生物降解的液体标记，具有出色的成像可视性，且伪影极少，适用于包括CT和MRI在内的各种成像方式。

2023 年 6 月，CIVCO Radiotherapy 收购了 Best Medical International, Inc.，扩大了其产品组合，进一步巩固了其在基准标记市场的地位。

2022 年 2 月，波士顿科学公司推出了一种旨在增强 MRI 相容性的新型基准标记，可提高病患安全性和治疗准确性。

目录

第一章：基准标记市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 基准标示市场（按产品）片段
    • 基准标示市场片段（按模式）
    • 基准标记市场片段（按癌症类型）
    • 基准标记市场片段（按最终用户）
    • 基准标记市场（按国家/地区）
    • 基准标示市场（按地区）
  • 竞争洞察

第三章：基准标示关键市场趋势

  • 基准标记市场驱动因素
    • 市场驱动因素的影响分析
  • 基准标记市场限制
    • 市场限制的影响分析
  • 基准标记市场机会
  • 基准标记市场未来趋势

第四章：基准标记产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：基准标记市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：基准标示市场格局

  • 2023年基准标示市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：基准标示市场 - 按产品

  • 概述
    • 按产品细分的市占率分析
    • 金属基标记物
      • 纯金标记
      • 金色组合标记
      • 其他金属标记物
    • 聚合物标记物
    • 其他基准标记

第 8 章：基准标示市场 - 按模式

  • 概述
    • 按方式分類的细分市场占有率分析
    • 扫描/输血
    • 超音波
    • 磁振造影
    • 放射治疗

第九章：基准标示市场－依癌症类型

  • 概述
    • 按癌症类型分析细分份额
    • 摄护腺癌
    • 肺癌
    • 胃癌
    • 乳癌
    • 其他癌症

第 10 章：基准标记市场 - 按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院和门诊设施
    • 独立放射治疗中心
    • 癌症研究中心

第 11 章：基准标示市场 - 按地理划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美基准标记主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按产品）
    • 北美市场规模及预测（依方式）
    • 北美市场规模及预测（按癌症类型）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲基准标线主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按产品）
    • 欧洲市场规模及预测（依方式）
    • 欧洲市场规模及预测（按癌症类型）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区基准标示主要製造商
    • 亚太市场规模及预测（按国家/地区）
    • 亚太市场规模及预测（按产品）
    • 亚太市场规模及预测（依方式）
    • 亚太市场规模及预测（按癌症类型）
    • 亚太市场规模及预测（依最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲基准标记关键製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按产品）
    • 拉丁美洲市场规模及预测（按方式）
    • 拉丁美洲市场规模及预测（按癌症类型）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲的基准标记主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（按产品）
    • 中东和非洲市场规模及预测（按方式）
    • 中东和非洲市场规模及预测（按癌症类型）
    • 中东和非洲市场规模及预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：关键供应商分析-基准标记产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • CIVCO Radiotherapy
    • Boston Scientific Corporation
    • IZI Medical Products
    • IBA
    • Naslund Medical AB
    • Medtronic
    • Best Medical International, Inc.
    • Nanovi A/S
    • Carbon Medical Technologies
    • Eckert & Ziegler
    • Innovative Oncology Solutions
    • QlRad Inc.
    • Stellar Medical
    • JJ-Medtech
    • QFIX
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5293

REPORT HIGHLIGHT

Fiducial Marker Market size was valued at USD 168.9 Million in 2024, expanding at a CAGR of 8.70% from 2024 to 2032.

In healthcare, a fiducial marker is a reference point or object placed in or on the body to assist with precise localization during medical imaging, diagnostic procedures, or treatment planning. These markers are commonly used in radiology, radiation therapy, and surgical navigation to align imaging data with anatomical structures. Fiducial markers can be external (placed on the skin) or internal (implanted into tissues or tumors). Materials such as gold, carbon, or polymer are often used due to their visibility in imaging modalities like CT, MRI, and X-rays. In cancer treatment, for example, fiducial markers are implanted near tumors to help guide radiation beams with high accuracy, minimizing damage to healthy tissue. Similarly, in neurosurgery or robotic-assisted surgeries, fiducials provide reference points that enhance navigation systems. Their use significantly improves procedural precision, outcomes, and patient safety by ensuring accurate targeting and consistent positioning throughout treatment or surgical interventions.

Fiducial Marker Market- Market Dynamics

Increasing Adoption of Image-Guided Therapies

The growing adoption of image-guided therapies in oncology, neurology, and cardiology is a key driver for the fiducial markers market. These procedures rely heavily on high-precision localization of anatomical targets to enhance treatment accuracy and reduce complications. Fiducial markers play a crucial role by serving as reliable reference points for aligning imaging data with the patient's anatomy, especially in complex interventions such as stereotactic radiosurgery or proton therapy. As healthcare providers increasingly prefer minimally invasive and targeted treatment options, the demand for fiducials has surged. Moreover, advancements in imaging technologies, including MRI, CT, and hybrid PET/CT systems, have expanded the utility of fiducial markers across diverse clinical settings. The rising prevalence of cancer and chronic diseases further contributes to the need for accurate treatment planning, positioning fiducial markers as an essential tool in modern therapeutic workflows. This trend is expected to drive sustained market growth.

FIDUCIAL MARKER Market- Key Insights

According to our research analyst, the global Fiducial Marker Market is expected to develop at a CAGR of approximately 8.70% between 2024-2032.

Segmented by Product in 2024, the Metal-Based Markers category dominated the market.

Based on Modality, the Ultrasound generated the most income in 2024.

Based on region, in 2024, North America was the region with the highest revenue.

Fiducial Marker Market- Segmentation Analysis:

The global Fiducial Marker market is divided into four categories: Product, Modality, Cancer Type, End User and Region.

The fiducial markers market is segmented by product into Metal-Based Markers, Polymer-Based Markers, and Other Fiducial Markers. Among these, Metal-Based Markers are expected to dominate the market due to their superior visibility and compatibility with various imaging modalities such as CT, MRI, and X-ray. Typically made from gold, platinum, or stainless steel, these markers provide high contrast and long-term stability within the body, making them ideal for procedures requiring repeated imaging, such as radiotherapy planning and image-guided surgery. Their durability and low risk of migration enhance procedural accuracy, particularly in oncology applications. The widespread clinical acceptance of metal-based fiducials, along with their proven efficacy in improving treatment outcomes, further supports their market leadership. As the demand for precision medicine and minimally invasive treatments continues to grow, the robust performance and reliability of metal-based markers position them as the preferred choice across global healthcare systems.

The fiducial markers market, when segmented by cancer type, includes Prostate Cancer, Lung Cancer, Gastric Cancer, Breast Cancer, and Other Cancers. Among these, Prostate Cancer accounts for the largest share and is expected to remain the dominant segment. This is largely due to the widespread use of fiducial markers in image-guided radiation therapy (IGRT) and stereotactic body radiation therapy (SBRT) for prostate cancer treatment. The prostate gland tends to shift slightly due to bladder and rectal filling, making accurate localization critical. Metal-based fiducial markers, especially gold markers, are routinely implanted in the prostate to ensure precise targeting during each treatment session, improving outcomes while minimizing damage to surrounding tissues. The rising global incidence of prostate cancer, along with increased awareness and adoption of advanced radiotherapy techniques, is driving the sustained demand for fiducial markers in this segment. Enhanced clinical protocols and reimbursement support further contribute to its market dominance.

Fiducial Marker Market- Geographical Insights

Geographically, the Fiducial Marker Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America holds a dominant position in the fiducial marker market, primarily driven by advanced healthcare infrastructure, high adoption rates of image-guided therapies, and significant investments in cancer treatment technologies. The United States, in particular, leads the market due to the high prevalence of cancer, especially prostate and lung cancer, which drives the demand for accurate diagnostic and therapeutic tools such as fiducial markers. Additionally, strong reimbursement policies, coupled with a well-established healthcare system, facilitate the widespread usage of fiducials in radiotherapy and surgical procedures. Furthermore, ongoing research and innovation in minimally invasive treatments and imaging technologies continue to support market growth. The region's dominance is also supported by the presence of key market players, further driving adoption and product development.

Europe is another key region contributing significantly to the fiducial marker market. The adoption of advanced healthcare technologies, coupled with a growing emphasis on precision medicine and targeted cancer therapies, has fostered the demand for fiducial markers in the region. Countries such as Germany, the UK, France, and Italy lead the market, owing to their highly developed healthcare systems and increasing cancer incidence rates. European healthcare providers are increasingly utilizing fiducial markers in image-guided radiation therapy, particularly for prostate, breast, and lung cancers. The region's strong regulatory frameworks, along with the support for clinical research and innovation, have paved the way for the growth of fiducial marker usage. Furthermore, the increasing preference for minimally invasive treatments and the growing focus on improving patient outcomes further boost the market.

Fiducial Marker Market- Competitive Landscape:

The competitive dynamics of the Fiducial Marker market are shaped by a mix of established players and emerging companies focused on innovation. Key market players such as CIVCO Radiotherapy, Boston Scientific Corporation, IZI Medical Products, Medtronic, and IBA hold significant market shares, offering a wide range of high-quality fiducial markers tailored for various medical imaging applications. These companies invest heavily in research and development to enhance product features, improve precision, and ensure regulatory compliance. New entrants, like Nanovi A/S and Innovative Oncology Solutions, are introducing advanced technologies such as next-gen fiducials with enhanced visibility and ease of implantation. This competitive landscape drives continuous advancements in the sector, fostering an environment of innovation that ultimately improves the accuracy and effectiveness of procedures. For instance, Medtronic continues to innovate in the field with its ongoing R&D and the development of advanced imaging technologies, maintaining its leadership in the market.

Recent Developments:

In October 2023, Nanovi A/S, a Danish medical device company specializing in liquid fiducial markers, was acquired by CQ Medical (formerly CIVCO Radiotherapy and Qfix). This acquisition integrates Nanovi's innovative BioXmark(R) technology into CQ Medical's portfolio, enhancing its offerings in high-precision radiation therapy. BioXmark(R) is a biodegradable liquid marker that provides excellent imaging visibility with minimal artifacts, making it suitable for various imaging modalities, including CT and MRI.

In June 2023, CIVCO Radiotherapy expanded its portfolio with the acquisition of Best Medical International, Inc., further strengthening its position in the fiducial marker market.

In February 2022, Boston Scientific Corporation launched a new fiducial marker designed for enhanced MRI compatibility, offering improved patient safety and treatment accuracy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FIDUCIAL MARKER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • CIVCO Radiotherapy
  • Boston Scientific Corporation
  • IZI Medical Products
  • IBA
  • Naslund Medical AB
  • Medtronic
  • Best Medical International, Inc.
  • Nanovi A/S
  • Carbon Medical Technologies
  • Eckert & Ziegler
  • Innovative Oncology Solutions
  • QlRad Inc.
  • Stellar Medical
  • JJ-Medtech
  • QFIX
  • Others

GLOBAL FIDUCIAL MARKER MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Metal-Based Markers
  • Pure Gold Markers
  • Gold Combination Markers
  • Other Metal-Based Markers
  • Polymer-Based Markers
  • Other Fiducial Markers

GLOBAL FIDUCIAL MARKER MARKET, BY MODALITY - MARKET ANALYSIS, 2019 - 2032

  • CT/CBCT
  • Ultrasound
  • MRI
  • Radiotherapy

GLOBAL FIDUCIAL MARKER MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032

  • Prostate Cancer
  • Lung Cancer
  • Gastric Cancer
  • Breast Cancer
  • Other Cancers

GLOBAL FIDUCIAL MARKER MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Outpatient Facilities
  • Independent Radiotherapy Centers
  • Cancer Research Centers

GLOBAL FIDUCIAL MARKER MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Fiducial Marker Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Fiducial Marker Market Snippet by Product
    • 2.1.2. Fiducial Marker Market Snippet by Modality
    • 2.1.3. Fiducial Marker Market Snippet by Cancer Type
    • 2.1.4. Fiducial Marker Market Snippet by End User
    • 2.1.5. Fiducial Marker Market Snippet by Country
    • 2.1.6. Fiducial Marker Market Snippet by Region
  • 2.2. Competitive Insights

3. Fiducial Marker Key Market Trends

  • 3.1. Fiducial Marker Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Fiducial Marker Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Fiducial Marker Market Opportunities
  • 3.4. Fiducial Marker Market Future Trends

4. Fiducial Marker Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Fiducial Marker Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Fiducial Marker Market Landscape

  • 6.1. Fiducial Marker Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Fiducial Marker Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2023 & 2032 (%)
    • 7.1.2. Metal-Based Markers
      • 7.1.2.1. Pure Gold Markers
      • 7.1.2.2. Gold Combination Markers
      • 7.1.2.3. Other Metal-Based Markers
    • 7.1.3. Polymer-Based Markers
    • 7.1.4. Other Fiducial Markers

8. Fiducial Marker Market - By Modality

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Modality, 2023 & 2032 (%)
    • 8.1.2. Ct/Cbct
    • 8.1.3. Ultrasound
    • 8.1.4. MRI
    • 8.1.5. Radiotherapy

9. Fiducial Marker Market - By Cancer Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Cancer Type, 2023 & 2032 (%)
    • 9.1.2. Prostate Cancer
    • 9.1.3. Lung Cancer
    • 9.1.4. Gastric Cancer
    • 9.1.5. Breast Cancer
    • 9.1.6. Other Cancers

10. Fiducial Marker Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals & Outpatient Facilities
    • 10.1.3. Independent Radiotherapy Centers
    • 10.1.4. Cancer Research Centers

11. Fiducial Marker Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Fiducial Marker Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Fiducial Marker Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Fiducial Marker Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Fiducial Marker Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Fiducial Marker Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Fiducial Marker Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. CIVCO Radiotherapy
    • 12.2.2. Boston Scientific Corporation
    • 12.2.3. IZI Medical Products
    • 12.2.4. IBA
    • 12.2.5. Naslund Medical AB
    • 12.2.6. Medtronic
    • 12.2.7. Best Medical International, Inc.
    • 12.2.8. Nanovi A/S
    • 12.2.9. Carbon Medical Technologies
    • 12.2.10. Eckert & Ziegler
    • 12.2.11. Innovative Oncology Solutions
    • 12.2.12. QlRad Inc.
    • 12.2.13. Stellar Medical
    • 12.2.14. JJ-Medtech
    • 12.2.15. QFIX
    • 12.2.16. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us